China Biopharmaceuticals in 2025
China's biopharmaceutical industry has undergone a dramatic transformation from generic drug manufacturing to genuine innovation. In 2024, the NMPA approved over 80 new molecular entities (NMEs) from domestic companies, including first-in-class therapies in oncology, autoimmune disease, and rare diseases. Chinese biotech companies have built world-class mRNA technology platforms following the COVID-19 pandemic experience, with several mRNA therapeutic candidates entering late-stage clinical trials. CDMO giants like WuXi Biologics and WuXi STA have become global partners for multinational pharma companies, while innovative biotechs including BeiGene, Legend Biotech, and Junshi Biosciences have achieved international regulatory approvals. This report examines China's biopharma innovation ecosystem, regulatory environment, and global expansion strategy.
TL;DR
NMPA approved 80+ domestic NMEs in 2024. Chinese pharma R&D spending exceeded 300 billion RMB. mRNA therapeutic candidates entered Phase 3 trials. BeiGene's Brukinsa achieved $2.5 billion in global revenue. WuXi Biologics served 600+ global clients. Biotech IPO recovery saw 15 listings raising 20 billion RMB.
Key Insights
NME Approvals
China's NMPA approved over 80 new molecular entities from domestic companies in 2024, spanning oncology (35 percent), immunology (20 percent), neuroscience (15 percent), and rare diseases (10 percent), reflecting the maturation of domestic drug discovery capabilities.
Pharma R&D Spending
Chinese pharmaceutical companies invested over 300 billion RMB ($41 billion) in R&D collectively, with BeiGene, Innovent Biologics, Hengrui Medicine, and Jiangsu Hengrui each exceeding 10 billion RMB in annual R&D expenditure.
BeiGene Global Revenue
BeiGene's Bruton's tyrosine kinase inhibitor Brukinsa (zanubrutinib) generated $2.5 billion in global revenue, approved in over 70 countries, making it the most successful drug developed by a Chinese biotech company internationally.
WuXi Biologics Scale
WuXi Biologics served over 600 global clients including 20 of the top 25 pharmaceutical companies, with 15+ projects in Phase 3 clinical trials and 2 BLA submissions, operating manufacturing facilities in China, Ireland, Singapore, and the US.
mRNA Platform Development
Chinese companies including Abogen Biosciences, StemiRNA Therapeutics, and Everest Medicines advanced mRNA therapeutic candidates into Phase 3 clinical trials for oncology and infectious diseases, leveraging domestically developed lipid nanoparticle delivery systems.
CDMO Export Growth
China's CDMO (Contract Development and Manufacturing Organization) exports grew 25 percent year-over-year, with WuXi STA, Pharmaron, and Tigermed serving an expanding roster of global biotech and pharma clients despite geopolitical headwinds.
Side-by-Side Comparison
| Company | Focus Area | Key Product/Platform | Global Presence | 2024 Revenue |
|---|---|---|---|---|
| BeiGene | Oncology | Brukinsa (BTK inhibitor) | 70+ countries | $2.5B (global) |
| WuXi Biologics | CDMO biologics | Dual-platform (mAb, bispecific) | Global operations | 18B RMB |
| Innovent Biologics | Oncology, immunology | Tyvyt (PD-1), biosimilars | US, EU filing | 7B RMB |
| Hengrui Medicine | Oncology, cardiovascular | Multiple NMEs | Emerging global | 22B RMB |
| Legend Biotech | CAR-T therapy | Carvykti (BCMA CAR-T) | US, EU, Japan | $1B+ |
Frequently Asked Questions
China's biopharma industry has made remarkable progress in innovation. Domestic NME approvals exceeded 80 in 2024, up from single digits a decade ago. Companies like BeiGene, Legend Biotech, and Junshi have achieved first-in-class or best-in-class drug candidates. However, the majority of new approvals remain me-too or me-better drugs in established target classes. True first-in-class innovation is still emerging, with perhaps 10-15 percent of domestic approvals representing genuinely novel mechanisms. The industry is transitioning from fast-follower to genuine innovator status.
China built significant mRNA technology capabilities during and after COVID-19. Companies like Abogen Biosciences (which partnered with Moderna-licensed technology initially before developing proprietary platforms), StemiRNA Therapeutics, and Everest Medicines have developed domestic lipid nanoparticle delivery systems and mRNA design tools. Several mRNA therapeutic candidates targeting oncology (personalized cancer vaccines) and infectious diseases have entered Phase 3 clinical trials. China's mRNA ecosystem now encompasses nucleoside synthesis, LNP formulation, and manufacturing at clinical and commercial scale.
Geopolitical tensions have significantly impacted Chinese biotech. The US BIOSECURE Act targets WuXi AppTec and other Chinese CDMOs, potentially restricting their access to US contracts and data. Some multinational pharma companies have begun diversifying supply chains away from Chinese CDMO partners. However, the impact has been uneven: innovative biotechs like BeiGene and Legend Biotech with strong clinical data and global regulatory approvals have largely maintained their international partnerships, while CDMO companies face greater challenges. Chinese biotechs are increasingly pursuing EU and Japanese regulatory approvals as alternative markets.